“…CCNA1 is the cyclin required for progression from S phase into G2, whereas CCNE1 is necessary for transition through the G1/S and G2/M checkpoints (Schafer, 1998). Increased CCN1A expression may be stimulated by the transcription factors MYB and HMGA1 (Muller et al, 1999;Reeves et al, 2001). In addition, downregulation of WT-1 is associated with increased expression of cyclin E1 (Loeb et al, 2002).…”
“…CCNA1 is the cyclin required for progression from S phase into G2, whereas CCNE1 is necessary for transition through the G1/S and G2/M checkpoints (Schafer, 1998). Increased CCN1A expression may be stimulated by the transcription factors MYB and HMGA1 (Muller et al, 1999;Reeves et al, 2001). In addition, downregulation of WT-1 is associated with increased expression of cyclin E1 (Loeb et al, 2002).…”
“…HTB-22), were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10mM HEPES, 100 units/mL penicillin G sodium and 100μg/mL streptomycin sulfate. For routine maintenance, almost confluent monolayer cultures of cells were digested to single cell suspensions by gentle trypsinization, washed with phosphate buffered saline (PBS), counted and seeded into 100 mm culture dishes, as previously described [13]. Clonal cell lines MCF7-7C-Cs8 and MCF7-7C-Cs9 are stably transfected derivatives of MCF7/Tet-"OFF" cells containing a tetracycline-regulated pTRE vector encoding Hemagglutinin (HA)-tagged HMGA1a cDNA, maintained in the presence of 100 μg/ml of hygromycin [13].…”
Section: Cell Culturementioning
confidence: 99%
“…For routine maintenance, almost confluent monolayer cultures of cells were digested to single cell suspensions by gentle trypsinization, washed with phosphate buffered saline (PBS), counted and seeded into 100 mm culture dishes, as previously described [13]. Clonal cell lines MCF7-7C-Cs8 and MCF7-7C-Cs9 are stably transfected derivatives of MCF7/Tet-"OFF" cells containing a tetracycline-regulated pTRE vector encoding Hemagglutinin (HA)-tagged HMGA1a cDNA, maintained in the presence of 100 μg/ml of hygromycin [13]. These different transgenic cell lines express high, but variable levels of transgenic HA-tagged HMGA1a protein when grown in medium lacking tetracycline (these are referred to as HMGA1 "ON" cells).…”
Section: Cell Culturementioning
confidence: 99%
“…These genes were chosen because microarray and other analyses indicated that HMGA1 proteins do not regulate the transcription of either gene in the cell lines being investigated (unpublished data), an important consideration given that these proteins can either positively or negatively regulate the transcription of a large number of genes in vivo (reviewed in: [12]). The cell lines used in this study include stable transgenic MCF7 human breast cancer epithelial cell lines that contain a tetracycline-regulated HMGA1a transgene which can be experimentally induced (or not) to over-express HMGA1 protein, as previously described [13]. For comparison, we also assayed the efficiency of UV-induced lesion removal in non-transgenic MCF7 cells that express little, or no, detectable endogenous HMGA1 and in human embryonic fibroblasts (IMR90 cells), which naturally over-expresses high levels of these proteins.…”
Previous work has established that stably-transfected human MCF7 cells over-expressing high mobility group A1 proteins (HMGA1) are deficient in global genomic repair (GGR) following exposure to either UV light or cisplatin. To investigate whether HMGA1 over-expression also interferes with gene-specific repair, we employed a rapid and convenient quantitative polymerase chain reaction assay for measuring repair in unique DNA sequences. Efficiency of UV-induced lesion removal was assessed for two genes in MCF7 cells either induced, or not, to over-express transgenic HMGA1 proteins: the constitutively active HPRT gene and the transcriptionally silent β-globin gene. As controls, similar experiments were also performed in non-transgenic MCF7 cells that do not express detectable levels of HMGA1 and in normal human embryonic fibroblasts that naturally overexpress HMGA1 proteins. Our results indicate that exposure of cells to a UV dose of 20 J/m 2 produced an average of 0.21 ± 0.03 lesions/kb and 0.19 ± 0.02 lesions/kb in the HPRT and β-globin genes, respectively, with no significant difference between HMGA1 over-expressing cells and nonexpressing cells. On the other hand, analysis of repair following UV exposure revealed that, compared to controls, HMGA1 over-expressing cells take considerably longer to repair photo-lesions in both the active HPRT and the silent β-globin loci, with non-expressing cells repairing 50% of lesions in HPRT 3-4 hours faster than HMGA1 over-expressing cells. Interestingly, the delay in repair is even more prolonged in the silent β-globin locus in HMGA1 over-expressing cells compared to control cells. To our knowledge, this is the first report of HMGA1 proteins inhibiting NER within specific genes located in either transcriptionally active "open", or inactive "closed", chromatin domains. Furthermore, taken together with previous findings, these results suggest that HMGA1 overexpression interferes with repair processes common to both the GGR and transcription coupled repair pathways.
“…The high mobility group A (HMGA) proteins are an important family of AT-hook chromatin remodeling proteins that orchestrate transcriptional complexes to regulate gene expression [1]. Recent studies have uncovered links between HMG AT-hook transcription factors and inflammation [1][2][3][4][5][6][7][8]. Moreover, emerging evidence also indicates that inflammatory pathways and downstream effects on tissues are important precursor lesions in diverse cancers [1].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.